InvestorsHub Logo
Followers 1028
Posts 23645
Boards Moderated 1
Alias Born 02/05/2014

Re: None

Sunday, 11/22/2015 1:19:36 PM

Sunday, November 22, 2015 1:19:36 PM

Post# of 26909
$SCIE FDA PMA APPROVAL/ DD REPORT! TARGETS 0045/006/008/014



Over the next 12 months, SpectraScience intends to:

· Market and sell the WavSTAT4 Optical Biopsy System colon cancer diagnostic application through PENTAX and other distribution channels in the European Union;

· Conduct country-specific evaluation trials to demonstrate the effectiveness and cost benefit of the WavSTAT4 Optical Biopsy System in each relevant European jurisdiction;

· Coordinate the creation and publication of scientific papers and presentations related to the country-specific evaluation trials to support widespread education and adoption of the WavSTAT4 ;

· Pursue the introduction of the WavSTAT4 colon cancer application in other international markets, in particular China, Saudi Arabia and India;

· Begin meeting with the FDA towards the preparation and submission of a Supplemental PMA filing with the FDA and plan for additional clinical trials to support eventual approval for sale in the United States;


· Begin the design and planning for the next generation of multi-modal fluorescence and broadband spectroscopy systems at our facility in San Diego, California.

· Continue to expand and refine our intellectual property portfolio.

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11014855








During the six months ended June 30, 2015, in conjunction with the sale of Convertible Debentures, the Company issued five year common stock purchase warrants to acquire up to 5,725,312 shares to holders of the Debentures. These warrants have exercise prices ranging from $0.06 to $0.09 per share.











Market Value1 $792,157 a/o Nov 20, 2015
Authorized Shares 746,915,000
Outstanding Shares 198,039,192 a/o Aug 14, 2015

-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float Not Available
Par Value 0.01